Autologous hematopoietic stem cell transplantation is an excellent treatment, especially for lymphoma patients and multiple myeloma patients, and is more effective than ordinary chemotherapy. Autologous hematopoietic stem cell transplantation is the process of isolating the patient’s own hematopoietic stem cells beforehand, then freezing them, and then pre-treating the frozen hematopoietic stem cells to lyse them quickly and then infusing them into the patient to restore hematopoietic reconstruction. Since autologous HSCs do not have the problem of rejection, and the pretreatment protocol is relatively light, the patient’s side effects such as bone marrow suppression are significantly reduced, and the cost to the patient is relatively low. It is now widely used in clinical practice, especially for patients with multiple myeloma and lymphoma, and autologous HSCT is an excellent treatment method. Therefore, autologous hematopoietic stem cell transplantation is very good.